Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.
| Autor: | Anandhakrishnan A; Ananthi Anandhakrishnan, Márta Korbonits, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6 BQ, United Kingdom., Korbonits M; Ananthi Anandhakrishnan, Márta Korbonits, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6 BQ, United Kingdom. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | World journal of diabetes [World J Diabetes] 2016 Dec 15; Vol. 7 (20), pp. 572-598. |
| DOI: | 10.4239/wjd.v7.i20.572 |
| Abstrakt: | Though the pathophysiology of clinical obesity is undoubtedly multifaceted, several lines of clinical evidence implicate an important functional role for glucagon-like peptide 1 (GLP-1) signalling. Clinical studies assessing GLP-1 responses in normal weight and obese subjects suggest that weight gain may induce functional deficits in GLP-1 signalling that facilitates maintenance of the obesity phenotype. In addition, genetic studies implicate a possible role for altered GLP-1 signalling as a risk factor towards the development of obesity. As reductions in functional GLP-1 signalling seem to play a role in clinical obesity, the pharmacological replenishment seems a promising target for the medical management of obesity in clinical practice. GLP-1 analogue liraglutide at a high dose (3 mg/d) has shown promising results in achieving and maintaining greater weight loss in obese individuals compared to placebo control, and currently licensed anti-obesity medications. Generally well tolerated, provided that longer-term data in clinical practice supports the currently available evidence of superior short- and long-term weight loss efficacy, GLP-1 analogues provide promise towards achieving the successful, sustainable medical management of obesity that remains as yet, an unmet clinical need. Competing Interests: Conflict-of-interest statement: Authors declare no conflict of interests for this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|